profile image for Dr Nigel Temperton

Dr Nigel Temperton

Senior Lecturer in Biological Sciences

Medway School of Pharmacy

 

Nigel obtained his BSc (Hons) in Microbiology and Genetics from University College London (UCL) in 1990 and an MSc in Applied Molecular Biology of Infectious Diseases (1992), PhD in Molecular Parasitology (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine (LSHTM). After his PhD, Nigel returned to UCL as a post-doctoral scientist at the Centre for Virology (Royal Free Campus). In 2003 Nigel transferred to the MRC/UCL Centre for Medical Molecular Virology initially as a senior post-doctoral scientist and subsequently progressed to the level of Principal Investigator, funded by the MRC and industry. He is currently a Senior Lecturer in Biological Sciences at the Medway School of Pharmacy. Nigel is a Senior Associate Member of the Royal Society of Medicine (RSM), a member of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV), the Biochemical Society and the Society for General Microbiology (SGM). In 2009 Nigel was elected as a member of the highly prestigious Medical Research Club, London.

back to top

My research interests lie primarily in emerging/re-emerging and transboundary viruses (SARS coronavirus, pandemic/inter-pandemic influenza, rabies/lyssaviruses) and the methods for their control, in particular, control by vaccination induced humoral responses. I have established novel virus antibody neutralization assays for high-containment viruses (Influenza H5N1/H7N1, SARS coronavirus and rabies) using retroviral and lentiviral vector technologies. In January 2011 I have established (in collaboration with Dr Simon Scott) the Viral Pseudotype Unit (VPU) within the School of Pharmacy, a purpose built, dedicated viral pseudotype R&D laboratory. The role of the VPU is to act as an interface between academia, industry, animal and public health laboratories with the purpose of translating basic virus research into in vitro cell culture based assays that can be readily employed for the efficacy testing of vaccines, antivirals and therapeutic antibodies. I maintain many active and productive collaborations (in the UK and worldwide) with academia (UCL, University of Oxford, University of Westminster, University of Nottingham), public/animal health laboratories (HPA/WHO/AHVLA/OiE), vaccine clinical trial centres (University of Siena and CEVAC, Ghent) and industry (vaccine and biotech companies). I currently have two PhD students (Eleonora Molesti and Francesca Ferrara) who are undertaking research projects on influenza.

Current Projects

  • The development of surface-engineered retroviral vectors to study the antigenic evolution of influenza H5 and H7 viruses in birds and humans.
  • The study of homosubtypic and heterosubtypic immunity to influenza viruses.
  • Comparative serology for influenza viruses in order to establish more accurate correlates of immunity.
  • The translation of "sequence-file serology" to public/animal health and industrial laboratories worldwide.
  • The development of cell entry assays for emerging bat viruses.
  • The design and development of pseudotype-based vaccines for emerging viruses.
back to top
  • Valkenburg S, Mallajosyula V, Li O, Chin A, Carnell G, Temperton N, Varadarajan R, and Poon L. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Scientific Reports. 2016, DOI: 10.1038/srep22666
  • Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T, Gilbert SC and Zhang Q. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.Vaccine. 2016 Feb 19. pii: S0264-410X(16)00170-5. doi: 10.1016/j.vaccine.2016.02.028.
  • Anto Vrdoljak, Evin Allen, Francesca Ferrara, Nigel J Temperton, Abina M Crean and Anne C Moore. Induction of Broad Immunity by Thermostabilised Vaccines Incorporated in Dissolvable Microneedles Using Novel Fabrication Methods. Journal of Controlled Release 2016, In Press
  • Temperton NJ. The Viral Pseudotype Unit: viral pseudotype R&D, dissemination and education. Future Virology. 2015; In Press
  • King B, Temperton N, Grehan K, Scott S, Wright E, Tarr A & Daly J. Technical considerations for the generation of novel pseudotyped viruses. Future Virology 2015, In Press
  • Grehan K, Ferrara F & Temperton NJ. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX 2015, 10.1016/j.mex.2015.09.003
  • Temperton NJ, Wright E & Scott SD. ‘Retroviral Pseudotypes – From Scientific Tools to Clinical Utility’ review article has been published online in the Encyclopedia of Life Sciences (DOI: 10.1002/9780470015902.a0021549.pub2).
  • Temperton NJ and Page M. Ebolavirus: pseudotypes, libraries and standards. Future Virology. 2015; In Press
  • Xiaoli Xiong, Davide Corti, Junfeng Liu, Debora Pinna, Mathilde Foglierini, Lesley J. Calder, Stephen R. Martin, Yi Pu Lin, Philip A. Walker, Patrick J. Collins, Isabella Monne, Amorsolo L. Suguitan Jr., Celia Santos, Nigel J. Temperton, Kanta Subbarao, Antonio Lanzavecchia, Steven J. Gamblin, and John J. Skehel. Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody PNAS 2015 ; published ahead of print July 13, 2015, doi:10.1073/pnas.1510816112
  • Mallajosyula VA, Citron M, Ferrara F, Temperton NJ, Liang X, Flynn JA and Varadarajan R (2015). Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype. Front. Immunol. 6:329. doi: 10.3389/fimmu.2015.00329
  • Bentley E, Mather S, Temperton N. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination. Vaccine. 2015; http://dx.doi.org/10.1016/j.vaccine.2015.04.071
  • Long J, Wright E, Molesti E, Temperton N and Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research 2015, 4:30 (doi: 10.12688/f1000research.6085.2)
  • Carnell GW, Ferrara F, Grehan K, Thompson CP and Temperton NJ (2015). Pseudotype-based neutralization assays for influenza: a systematic analysis. Front. Immunol. 6:161. doi: 10.3389/fimmu.2015.00161
  • Ferrara F, Molesti E, Temperton NJ. The application of pseudotypes to influenza pandemic preparedness. Future Virology. 2015; In Press
  • Benfield C, Smith SE, Wright E, Wash RS, Ferrara F, Temperton NJ, Kellam P. Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses. J Gen Virol. 2015 Jan 22. pii: vir.0.000058. doi: 10.1099/vir.0.000058.
  • Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection. Antiviral Res. 2014 Dec 13;114C:106-112. doi: 10.1016/j.antiviral.2014.12.008.
  • Lacek K, Urbanowicz RA, Troise F, De Lorenzo C, Severino V, Di Maro A, Tarr AW, Ferrara F, Ploss A, Temperton N, Ball JK, Nicosia A, Cortese R, Pessi A. Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. J Biol Chem. 2014 Dec 12;289(50):35015-28. doi: 10.1074/jbc.M114.591826. Epub 2014 Oct 23.
  • Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines. 2014; 2(4):707-734.
  • Mather ST, Wright E, Scott SD, Temperton NJ. Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation -assay-based diagnostic kit. J Virol Methods. 2014 Oct 5;210C:51-58. doi: 10.1016/j.jviromet.2014.09.021.
  • Molesti E, Wright E, Terregino C, Rahman R, Cattoli G, Temperton NJ. Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J Immunol Res. 2014;2014:457932. doi: 10.1155/2014/457932. Epub 2014 Jul 3.
  • Molesti E, Ferrara F, Lapini G, Montomoli E, Temperton N. Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals. Biomed Res Int. 2014;2014:231365. doi: 10.1155/2014/231365. Epub 2014 Jun 11.
  • Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, Sarma SP, Flynn JA, Temperton NJ, Liang X, Varadarajan R. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2514-23. doi: 10.1073/pnas.1402766111. Epub 2014 Jun 9.
  • Wallerström S, Lagerqvist N, Temperton NJ, Cassmer M, Moreno A, Karlsson M, Leijon M, Lundkvist A, Falk KI. Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests. Infect Ecol Epidemiol. 2014 Jan 15;4. doi: 10.3402/iee.v4.23011. eCollection 2014 Jan 15
  • Sarah Smith, Mark Gibson, Rachael Wash, Francesca Ferrara, Edward Wright, Nigel Temperton, Paul Kellam, and Mark Fife. Chicken IFITM3 restricts influenza viruses and lyssaviruses in vitro (2013),  Journal of Virology Dec;87(23):12957-66. doi: 10.1128/JVI.01443-13. Epub 2013 Sep 25.
  • Eleonora Molesti, Adelaide Milani, Calogero Terregino, Giovanni Cattoli, and Nigel  J. Temperton, “Comparative Serological Assays for the Study of H5 and H7 Avian Influenza Viruses,” Influenza Research and Treatment, vol. 2013, Article ID 286158, 9 pages, 2013. doi:10.1155/2013/286158
  • Mather S, Scott S, Temperton N, Wright E, King B & Daly J. Current progress with serological assays for exotic emerging / re-emerging viruses. Future Virology, August 2013, Vol. 8, No. 8, Pages 745-755.
  • Mullarkey CE, Boyd A, van Laarhoven A, Lefevre EA, Carr BV, Baratelli M, Molesti E, Temperton NJ, Butter C, Charleston B, Lambe T, Gilbert SC. Improved adjuvanting of seasonal influenza vaccines: Pre-clinical studies of MVA-NP+M1 co-administration with inactivated influenza vaccine. Eur J Immunol, Published online ahead of print April 16, 2013, doi: 10.1002/eji.201242922
  • Shelton H, Roberts KL, Molesti E, Temperton N, Barclay WS (2013). Mutations in hemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility: Journal of General Virology, Published online ahead of print March 13, 2013, doi: 10.1099/vir.0.050526-0
  • Waleed H. Mahallawi, Anand V. Kasbekar, Maxwell S. McCormick, Katja Hoschler, Nigel Temperton, Samuel C. Leong, Helen Beer, Francesca Ferrara, Paul S. McNamara and Qibo Zhang. 2009 H1N1 infection primes for immunological memory in human nasal-associated lymphoid tissue that offers cross-reactive immunity to H1N1 and avian H5N1 viruses. Journal of Virology 2013 Mar 6. (Epub ahead of print).
  • Francesca Ferrara, Eleonora Molesti, Eva Böttcher-Frieberthäuser, Giovanni Cattoli, Davide Corti, Simon D Scott and Nigel J Temperton. The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. J Mol Genet Med 2013, Vol 7, 309-314
  • Eleonora Molesti, Giovanni Cattoli, Francesca Ferrara, Eva Böttcher-Frieberthäuser, Calogero Terregino, Nigel Temperton. The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses. J Mol Genet Med 2013, Vol 7, 315-320
  • Simon Scott, Eleonora Molesti, Nigel Temperton, Francesca Ferrara, Eva Böttcher-Friebertshäuser and Janet Daly. The use of equine influenza pseudotypes for serological screening. J Mol Genet Med 2012, Vol 6, 304-308
  • Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF,Temperton N, Langedijk JPM, Skehel JJ, Lanzavecchia A (2011). A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins: Science 333, 850-856. http://www.sciencemag.org/content/333/6044/850.abstract?sid=c3917e2d-c43f-42fb-b4bc-688d17fd62a7
  • Cattoli G, Milani A, Temperton N, Zecchin B, Buratin A, Molesti E, Aly MM, Arafa A, Capua I (2011).
    Antigenic drift in H5N1 avian influenza in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to human influenza: Journal of Virology 85, 8718-8724.
  • Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ (2011). Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules: PLoS One 6:e17665.
  • Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X (2011). Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection: Journal of Infectious Diseases 203, 1063-1072.
  • Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, Shelton H, Molesti E,Temperton NJ, Barclay WS, Jones IM (2011). Adjuvant free immunisation with Hemagglutinin-Fc fusion proteins as an approach to influenza vaccines: Journal of Virology 85, 3010-3014.
  • Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A (2010). Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine: Journal of Clinical Investigation 120, 1663-167.

Books

  • Temperton NJ, Wright E, Scott S. Retroviral Pseudotypes - from scientific tools to clinical utility. Encyclopaedia of Life Sciences. 2015; In Press
  • Temperton NJ (2010). The Use of Retroviral Pseudotypes for the Measurement of Antibody Responses to SARS Coronavirus. Chapter 17 in Lal SK (ed.) Molecular Biology of the SARS-Coronavirus. Berlin: Springer-Verlag.
  • Temperton NJ, Wright E (2009) Retroviral Pseudotypes. In: Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0021549.

Patents

  • AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES: WO2009147248 (A2) ? 2009-12-10

Full list of publications

  • Valkenburg S, Mallajosyula V, Li O, Chin A, Carnell G, Temperton N, Varadarajan R, and Poon L. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Scientific Reports. 2016, DOI: 10.1038/srep22666
  • Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T, Gilbert SC and Zhang Q. Activation of cross-reactive mucosal T and B cell responses in human nasopharynx associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.Vaccine. 2016 Feb 19. pii: S0264-410X(16)00170-5. doi: 10.1016/j.vaccine.2016.02.028.
  • Anto Vrdoljak, Evin Allen, Francesca Ferrara, Nigel J Temperton, Abina M Crean and Anne C Moore. Induction of Broad Immunity by Thermostabilised Vaccines Incorporated in Dissolvable Microneedles Using Novel Fabrication Methods. Journal of Controlled Release 2016, In Press
  • Temperton NJ. The Viral Pseudotype Unit: viral pseudotype R&D, dissemination and education. Future Virology. 2015; In Press
  • King B, Temperton N, Grehan K, Scott S, Wright E, Tarr A & Daly J. Technical considerations for the generation of novel pseudotyped viruses. Future Virology 2015, In Press
  • Grehan K, Ferrara F & Temperton NJ. An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX 2015, 10.1016/j.mex.2015.09.003
  • Temperton NJ, Wright E & Scott SD. ‘Retroviral Pseudotypes – From Scientific Tools to Clinical Utility’ review article has been published online in the Encyclopedia of Life Sciences (DOI: 10.1002/9780470015902.a0021549.pub2).
  • Temperton NJ and Page M. Ebolavirus: pseudotypes, libraries and standards. Future Virology. 2015; In Press
  • Xiaoli Xiong, Davide Corti, Junfeng Liu, Debora Pinna, Mathilde Foglierini, Lesley J. Calder, Stephen R. Martin, Yi Pu Lin, Philip A. Walker, Patrick J. Collins, Isabella Monne, Amorsolo L. Suguitan Jr., Celia Santos, Nigel J. Temperton, Kanta Subbarao, Antonio Lanzavecchia, Steven J. Gamblin, and John J. Skehel. Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody PNAS 2015 ; published ahead of print July 13, 2015, doi:10.1073/pnas.1510816112
  • Mallajosyula VA, Citron M, Ferrara F, Temperton NJ, Liang X, Flynn JA and Varadarajan R (2015). Hemagglutinin sequence conservation guided stem immunogen design from influenza A H3 subtype. Front. Immunol. 6:329. doi: 10.3389/fimmu.2015.00329
  • Bentley E, Mather S, Temperton N. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination. Vaccine. 2015; http://dx.doi.org/10.1016/j.vaccine.2015.04.071
  • Long J, Wright E, Molesti E, Temperton N and Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research 2015, 4:30 (doi: 10.12688/f1000research.6085.2)
  • Carnell GW, Ferrara F, Grehan K, Thompson CP and Temperton NJ (2015). Pseudotype-based neutralization assays for influenza: a systematic analysis. Front. Immunol. 6:161. doi: 10.3389/fimmu.2015.00161
  • Ferrara F, Molesti E, Temperton NJ. The application of pseudotypes to influenza pandemic preparedness. Future Virology. 2015; In Press
  • Benfield C, Smith SE, Wright E, Wash RS, Ferrara F, Temperton NJ, Kellam P. Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses. J Gen Virol. 2015 Jan 22. pii: vir.0.000058. doi: 10.1099/vir.0.000058.
  • Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection. Antiviral Res. 2014 Dec 13;114C:106-112. doi: 10.1016/j.antiviral.2014.12.008.
  • Lacek K, Urbanowicz RA, Troise F, De Lorenzo C, Severino V, Di Maro A, Tarr AW, Ferrara F, Ploss A, Temperton N, Ball JK, Nicosia A, Cortese R, Pessi A. Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. J Biol Chem. 2014 Dec 12;289(50):35015-28. doi: 10.1074/jbc.M114.591826. Epub 2014 Oct 23.
  • Trombetta CM, Perini D, Mather S, Temperton N, Montomoli E. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines. 2014; 2(4):707-734.
  • Mather ST, Wright E, Scott SD, Temperton NJ. Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation -assay-based diagnostic kit. J Virol Methods. 2014 Oct 5;210C:51-58. doi: 10.1016/j.jviromet.2014.09.021.
  • Molesti E, Wright E, Terregino C, Rahman R, Cattoli G, Temperton NJ. Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J Immunol Res. 2014;2014:457932. doi: 10.1155/2014/457932. Epub 2014 Jul 3.
  • Molesti E, Ferrara F, Lapini G, Montomoli E, Temperton N. Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals. Biomed Res Int. 2014;2014:231365. doi: 10.1155/2014/231365. Epub 2014 Jun 11.
  • Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, Sarma SP, Flynn JA, Temperton NJ, Liang X, Varadarajan R. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2514-23. doi: 10.1073/pnas.1402766111. Epub 2014 Jun 9.
  • Wallerström S, Lagerqvist N, Temperton NJ, Cassmer M, Moreno A, Karlsson M, Leijon M, Lundkvist A, Falk KI. Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests. Infect Ecol Epidemiol. 2014 Jan 15;4. doi: 10.3402/iee.v4.23011. eCollection 2014 Jan 15
  • Sarah Smith, Mark Gibson, Rachael Wash, Francesca Ferrara, Edward Wright, Nigel Temperton, Paul Kellam, and Mark Fife. Chicken IFITM3 restricts influenza viruses and lyssaviruses in vitro (2013),  Journal of Virology Dec;87(23):12957-66. doi: 10.1128/JVI.01443-13. Epub 2013 Sep 25.
  • Eleonora Molesti, Adelaide Milani, Calogero Terregino, Giovanni Cattoli, and Nigel  J. Temperton, “Comparative Serological Assays for the Study of H5 and H7 Avian Influenza Viruses,” Influenza Research and Treatment, vol. 2013, Article ID 286158, 9 pages, 2013. doi:10.1155/2013/286158
  • Mather S, Scott S, Temperton N, Wright E, King B & Daly J. Current progress with serological assays for exotic emerging / re-emerging viruses. Future Virology, August 2013, Vol. 8, No. 8, Pages 745-755.
  • Mullarkey CE, Boyd A, van Laarhoven A, Lefevre EA, Carr BV, Baratelli M, Molesti E, Temperton NJ, Butter C, Charleston B, Lambe T, Gilbert SC. Improved adjuvanting of seasonal influenza vaccines: Pre-clinical studies of MVA-NP+M1 co-administration with inactivated influenza vaccine. Eur J Immunol, Published online ahead of print April 16, 2013, doi: 10.1002/eji.201242922
  • Shelton H, Roberts KL, Molesti E, Temperton N, Barclay WS (2013). Mutations in hemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility: Journal of General Virology, Published online ahead of print March 13, 2013, doi: 10.1099/vir.0.050526-0
  • Waleed H. Mahallawi, Anand V. Kasbekar, Maxwell S. McCormick, Katja Hoschler, Nigel Temperton, Samuel C. Leong, Helen Beer, Francesca Ferrara, Paul S. McNamara and Qibo Zhang. 2009 H1N1 infection primes for immunological memory in human nasal-associated lymphoid tissue that offers cross-reactive immunity to H1N1 and avian H5N1 viruses. Journal of Virology 2013 Mar 6. (Epub ahead of print).
  • Francesca Ferrara, Eleonora Molesti, Eva Böttcher-Frieberthäuser, Giovanni Cattoli, Davide Corti, Simon D Scott and Nigel J Temperton. The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. J Mol Genet Med 2013, Vol 7, 309-314
  • Eleonora Molesti, Giovanni Cattoli, Francesca Ferrara, Eva Böttcher-Frieberthäuser, Calogero Terregino, Nigel Temperton. The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses. J Mol Genet Med 2013, Vol 7, 315-320
  • Simon Scott, Eleonora Molesti, Nigel Temperton, Francesca Ferrara, Eva Böttcher-Friebertshäuser and Janet Daly. The use of equine influenza pseudotypes for serological screening. J Mol Genet Med 2012, Vol 6, 304-308
  • Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JPM, Skehel JJ, Lanzavecchia A (2011). A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins: Science 333, 850-856.
  • Cattoli G, Milani A, Temperton N, Zecchin B, Buratin A, Molesti E, Aly MM, Arafa A, Capua I (2011). Antigenic drift in H5N1 avian influenza in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to human influenza: Journal of Virology 85, 8718-8724.
  • Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ (2011). Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules: PLoS One 6:e17665.
  • Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X (2011). Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection: Journal of Infectious Diseases 203, 1063-1072.
  • Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, Shelton H, Molesti E, Temperton NJ, Barclay WS, Jones IM (2011). Adjuvant free immunisation with Hemagglutinin-Fc fusion proteins as an approach to influenza vaccines: Journal of Virology 85, 3010-3014.
  • Wright E, Hayman DT, Vaughan A, Temperton NJ, Wood JL, Cunningham AA, Suu-Ire R, Weiss RA, Fooks AR (2010). Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses: Virology 408, 183-189.
  • Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A (2010). Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine: Journal of Clinical Investigation 120, 1663-1673.
  • Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B (2009). Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 Influenza viruses: Vaccine 27, 5998-6003.
  • Ascione A, Capecchi B, Campitelli L, Imperiale V, Flego M, Zamboni S, Gellini M, Alberini I, Pittiglio E, Donatelli I, Temperton NJ, Cianfriglia M (2009). Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1: Antiviral Research 83, 238-244.
  • Oh S, Selleck P, Temperton NJ, Chan PK, Manavis J, Higgins G, Burrell CJ, Kok T (2009). Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 Viruses: Journal of Virological Methods 157, 161-167.
  • Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA, Brenchley JM, Douek DC, Mongkolsapaya J, Tran BH, Lin SC, Screaton GR, Hou JL, McMichael AJ, Xu XN (2008). T Cell Responses to Whole SARS Coronavirus in Humans: Journal of Immunology 181, 5490-5500.
  • Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA (2008). Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison: Journal of General Virology 89, 2204-2213.
  • Su CY, Wang SY, Shie JJ, Jeng KS, Temperton NJ, Fang JM, Wong CH, Cheng YS (2008). In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral Research 79, 199-205.
  • Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, Hien VM, Ha DQ, de Jong MD, Zambon M, Takeuchi Y, Weiss RA (2007). A Sensitive Retroviral Pseudotype Assay for Influenza H5N1 neutralizing antibodies: Influenza and other respiratory viruses 1, 105-112.
  • Dye C, Temperton N, Siddell SG (2007). Type 1 feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines: Journal of General Virology 88, 1753-1760.
  • Moyes D, Martin A, Sawcer S, Temperton N, Worthington J, Griffiths DJ, Venables PJ (2005). The distribution of the endogenous retroviruses HERV-K113 and -K115 in health and disease: Genomics 86, 336-341.
  • Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeushi Y, Weiss RA (2005). Longitudinally profiling neutralizing antibody response to SARS Coronavirus with pseudotypes: Emerging Infectious Diseases 11, 411-416.
  • Temperton NJ, Lawson KM, Quenelle DC, Zuckerman JN, Kern E, Griffiths PD, Emery VC (2003). Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminium phosphate and CpG ODN: Journal of Medical Virology 70, 86-90.
  • Temperton NJ (2002). DNA vaccines against cytomegalovirus: current progress: International Journal of Antimicrobial Agents 19, 169-172.
  • Wilkinson SR, Temperton NJ, Mondragon A, Kelly JM (2000). Distinct mitochondrial and cytosolic enzymes mediate trypanothione-dependent peroxide metabolism in Trypanosoma cruzi: Journal of Biological Chemistry 275, 8220-8225.
  • Temperton NJ, Wilkinson SR, Meyer DJ, Kelly JM (1998). Overexpression of superoxide dismutase in Trypanosoma cruzi results in increased sensitivity to the trypanocidal agents gentian violet and benznidazole: Molecular and Biochemical Parasitology 96, 167-176.
  • Temperton NJ, Wilkinson SR, Kelly JM (1996). Cloning of an Fe-superoxide dismutase gene homologue from Trypanosoma cruzi: Molecular and Biochemical Parasitology 76, 339-343.
back to top

Tel: +44 (0) 1634 202935
Fax: +44 (0) 1634 883927

Copyright © Medway School of Pharmacy
Last Updated 01/03/2016
Banner photo by Maria Kaloudi.